Total trials
123
Active
34
Phase 3
2
Total enrollment
123,067
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Gentamicin + narrow spectrum betalactam | — | — | — | — | — | 1 | |
| Cefotaxime | — | — | — | — | — | 1 | |
| Piperacillin-tazobactam | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 2 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Standard therapy | — | — | — | — | — | 1 | |
| Precision therapy | — | — | — | — | — | 1 | |
| Nicotinamide ribonucleoside | — | — | — | — | — | 1 |
Next readouts
- 2024-09-03
- 2026-06-10
- 2028-01-31
- 2028-06
Top conditions
- Heart Failure5
- Substance Use Disorders3
- Bipolar Disorder3
- Breast Cancer3
- Hip Fractures3
- COVID2
- Fatigue Post Viral2
- Mental Disorders2
Frequently asked questions about University Hospital, Akershus
- How many clinical trials does University Hospital, Akershus have on ClinicalTrials.gov?
- University Hospital, Akershus is listed as the lead sponsor on 123 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Akershus's trials are in Phase 3?
- 2 of University Hospital, Akershus's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does University Hospital, Akershus focus on?
- University Hospital, Akershus's most-studied conditions on ClinicalTrials.gov are Heart Failure, Substance Use Disorders, Bipolar Disorder, Breast Cancer, Hip Fractures.
- When are University Hospital, Akershus's next clinical trial readouts?
- University Hospital, Akershus has 4 upcoming primary-completion readouts tracked here; the soonest is “NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia”, expected around 2024-09-03.